Online citations, reference lists, and bibliographies.

A Review- Emerging Use Of Nano-Based Carriers In Diagnosis And Treatment Of Cancer-Novel Approaches

Yaqub Khan, Brijesh Kumar Saroj, Maryada Roy, Irfan Aziz
Published 2015 · Materials Science, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Despite intensive research efforts, cancer remains one of the leading causes of death in the world. Many new methods and techniques have been developed in order to improve diagnosis and treatment, often promising in the beginning, but with limited results during the course of their application. In recent years, there has been an unprecedented expansion in the field of nanomedicine with the development of new nanoparticles for the diagnosis and treatment of cancer. Nanoparticles have unique biological properties given their small size and large surface area-to-volume ratio, which allows them to bind, absorb, and carry compounds such as small molecule drugs, DNA, RNA, proteins, and probes with high efficiency. Their tunable size, shape, and surface characteristics also enable them to have high stability, high carrier capacity, the ability to incorporate both hydrophilic and hydrophobic substances and compatibility with different administration routes, thereby making them highly attractive in many aspects of oncology. The expansion of novel nanoparticles for drug delivery is an exciting and challenging research filed, in particular for the delivery of emerging cancer therapies, including small interference RNA (siRNA) and microRNA (miRNAs)-based molecules.
This paper references
10.1126/scitranslmed.3003651
Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile
Jeffrey Hrkach (2012)
10.1016/j.biomaterials.2009.06.026
Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier.
Todd L Kaneshiro (2009)
10.1016/j.leukres.2008.06.028
In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.
P. Tardi (2009)
10.1007/s00330-002-1721-7
Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications
P. Reimer (2002)
10.1016/j.tibtech.2008.04.005
Multifunctional nanoparticles--properties and prospects for their use in human medicine.
Nuria Sanvicens (2008)
10.1016/S0022-2836(65)80093-6
Diffusion of univalent ions across the lamellae of swollen phospholipids.
A. Bangham (1965)
10.1038/nbt927
The use of nanocrystals in biological detection
P. Alivisatos (2004)
10.3322/CA.2007.0003
Application of Nanotechnology in Cancer Therapy and Imaging
X. Wang (2008)
10.1016/S0142-9612(99)00125-8
Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles.
C. E. Soma (2000)
10.1007/PL00006740
Interaction between gemcitabine and mitomycin-C in vitro
T. T. Aung (2000)
10.1007/s11060-010-0389-0
Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme
K. Maier-Hauff (2010)
10.1038/nature03794
Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system
Shiladitya Sengupta (2005)
10.1002/smll.200900466
Gold nanoparticles of diameter 1.4 nm trigger necrosis by oxidative stress and mitochondrial damage.
Y. Pan (2009)
10.1016/S0065-2571(00)00013-3
The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting.
H. Maeda (2001)
10.1016/j.taap.2009.09.014
Effects and uptake of gold nanoparticles deposited at the air-liquid interface of a human epithelial airway model.
C. Brandenberger (2010)
10.2147/IJN.S35832
Functionalized carbon nanotubes: biomedical applications
Sandhya Vardharajula (2012)
10.2165/11204910-000000000-00000
Mifamurtide: a review of its use in the treatment of osteosarcoma.
J. Frampton (2010)
10.1002/cmdc.200700121
Co‐Delivery of Hydrophobic and Hydrophilic Drugs from Nanoparticle–Aptamer Bioconjugates
L. Zhang (2007)
10.2165/00003088-200342130-00002
Macromolecular Therapeutics
K. Greish (2003)
10.1038/nature08956
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
M. Davis (2010)
10.1158/0008-5472.CAN-05-4007
Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.
D. Drummond (2006)
10.1023/B:BMMD.0000031747.05317.81
Molecular Imaging Applications in Nanomedicine
K. C. Li (2004)
10.2147/IJN.S596
Drug delivery and nanoparticles: Applications and hazards
W. D. de Jong (2008)
10.1002/etc.1880
Metal-based nanoparticles in soil: fate, behavior, and effects on soil invertebrates.
Paula S. Tourinho (2012)
10.1097/JTO.0b013e31817c6b68
Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer
M. O'brien (2008)
10.1517/17425247.5.3.263
Emerging application of quantum dots for drug delivery and therapy
Lifeng Qi (2008)
10.1080/02656730601175479
Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: Results of a prospective phase I trial
M. Johannsen (2007)
10.1016/S0142-9612(96)00077-4
Nanotechnology for biomaterials engineering: structural characterization of amphiphilic polymeric nanoparticles by 1H NMR spectroscopy.
J. Hrkach (1997)
Liposomal daunorubicin as treatment for Kaposi’s sarcoma
Christin E Petre (2007)
10.1093/ANNONC/MDM374
Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer.
D.-W. Kim (2007)
10.2147/IJN.S21523
Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab
Parisa Yousefpour (2011)
10.1023/A:1024431218327
Synergy Between 3′Azido-3′deoxythymidine and Paclitaxel in Human Pharynx FaDu Cells
J. S. Johnston (2004)
10.1289/ehp.8284
A Toxicologic Review of Quantum Dots: Toxicity Depends on Physicochemical and Environmental Factors
R. Hardman (2006)
10.1021/JA0546525
A fullerene-paclitaxel chemotherapeutic: synthesis, characterization, and study of biological activity in tissue culture.
T. Y. Zakharian (2005)
10.1097/CCO.0b013e328351fb29
Clinical development of new formulations of cytotoxics in solid tumors
Hatem A. Azim (2012)
10.1007/s11095-010-0233-4
Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release
C. Oerlemans (2010)
10.1080/10408440600570233
A Review of Carbon Nanotube Toxicity and Assessment of Potential Occupational and Environmental Health Risks
C. Lam (2006)
10.1007/s00280-012-2042-4
Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine
J. Silverman (2012)
10.1016/J.CHEMBIOL.2004.10.016
Synthesis and functional evaluation of DNA-assembled polyamidoamine dendrimer clusters for cancer cell-specific targeting.
Youngseon Choi (2005)
10.1016/S0168-3659(01)00294-2
Chitosan nanoparticles as delivery systems for doxorubicin.
K. Janes (2001)
10.2165/00003088-200645120-00002
Pharmacology of Drugs Formulated with DepoFoam™
M. Angst (2006)
10.3727/000000006783980937
Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios.
T. Harasym (2007)
10.1208/s12249-010-9561-2
Recent Advancement of Chitosan-Based Nanoparticles for Oral Controlled Delivery of Insulin and Other Therapeutic Agents
Anumita Chaudhury (2010)
10.1016/j.ejmech.2008.04.021
Targeting cancer cells with biotin-dendrimer conjugates.
W. Yang (2009)
The Nanomedicine Revolution: Part 2: Current and Future Clinical Applications
Ventola Cl (2012)
10.1016/j.jconrel.2012.03.020
Doxil®--the first FDA-approved nano-drug: lessons learned.
Y. Barenholz (2012)
10.1016/S0168-3659(01)00324-8
Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy.
L. Xu (2001)
10.2174/157340711795163866
CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development
C. Young (2011)
10.1172/JCI45600
Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma.
M. Benezra (2011)
10.1007/s10637-011-9757-7
Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum
J. Lee (2011)
10.1093/ANNONC/MDH092
Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer.
Y. Matsumura (2004)
10.1158/0008-5472.CAN-08-1468
Drug delivery with carbon nanotubes for in vivo cancer treatment.
Zhuang Liu (2008)
Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
J. Wu (2007)
10.1080/10611860802473154
Surface-engineered dendrimers for dual drug delivery: A receptor up-regulation and enhanced cancer targeting strategy
Rakesh K Tekade (2008)
10.1634/THEONCOLOGIST.12-8-991
FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
P. Dinndorf (2007)
10.1289/ehp.7021
Manufactured Nanomaterials (Fullerenes, C60) Induce Oxidative Stress in the Brain of Juvenile Largemouth Bass
E. Oberdörster (2004)
10.1054/bjoc.2001.2027
Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants
V. Pavillard (2001)
10.1158/1078-0432.CCR-08-0515
Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors
G. Batist (2009)
10.1158/1535-7163.MCT-09-0243
Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo
P. Tardi (2009)
10.1159/000059570
Transcatheter Arterial Embolization with Zinostatin Stimalamer for Hepatocellular Carcinoma
T. Okusaka (2002)
10.1002/1521-3773(20001201)39:23<4254::AID-ANIE4254>3.0.CO;2-O
Functionalized Fullerene as an Artificial Vector for Transfection.
E. Nakamura (2000)
10.1126/scitranslmed.3001963
The Fate and Toxicity of Raman-Active Silica-Gold Nanoparticles in Mice
A. Thakor (2011)
10.1021/mp800240j
Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells.
Srinivas Ganta (2009)
10.1080/08982100500364081
6-Mercaptopurine and Daunorubicin Double Drug Liposomes—Preparation, Drug-Drug Interaction and Characterization
Vineet Agrawal (2005)
10.2147/IJN.S38330
Design and application of chitosan microspheres as oral and nasal vaccine carriers: an updated review
M. A. Islam (2012)
10.4314/TJPR.V8I3.44547
Nanotechnology and Drug Delivery Part 2: Nanostructures for Drug Delivery
N. Ochekpe (2009)
10.1038/nbt.1549
Synergistic drug combinations improve therapeutic selectivity
J. Lehar (2009)
10.3390/s120201657
Noble Metal Nanoparticles for Biosensing Applications
G. Doria (2012)
10.1007/s10637-012-9921-8
First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies
G. Weiss (2012)
10.1158/1535-7163.MCT-06-0118
Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice
L. Mayer (2006)
Transport of molecules in the tumor interstitium: a review.
R. Jain (1987)
10.1517/17425247.2013.758631
Hyperthermia-induced drug targeting
Jonathan P. May (2013)
10.1155/2013/456409
Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review
J. Lao (2013)
10.1016/J.CES.2005.06.019
Inorganic nanoparticles as carriers for efficient cellular delivery
Z. P. Xu (2006)
10.1023/A:1012128907225
Chitosan and Chitosan/Ethylene Oxide-Propylene Oxide Block Copolymer Nanoparticles as Novel Carriers for Proteins and Vaccines
P. Calvo (2004)
10.1146/annurev-med-040210-162544
Nanoparticle delivery of cancer drugs.
A. Wang (2012)
10.1016/J.ADDR.2005.09.018
Dendrimers in biomedical applications--reflections on the field.
Sönke Svenson (2005)
10.1016/j.toxlet.2013.02.009
In vitro nanotoxicity of single-walled carbon nanotube-dendrimer nanocomplexes against murine myoblast cells.
J. Cancino (2013)
10.1155/2010/796303
Cancer therapy based on nanomaterials and nanocarrier systems
Weili Qiao (2010)
10.1186/1556-276X-6-482
Nanoliposomes for encapsulation and delivery of the potential antitumoral methyl 6-methoxy-3-(4-methoxyphenyl)-1H-indole-2-carboxylate
Ana S. Abreu (2011)
10.1016/J.JCONREL.2007.05.038
Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents.
Y. Bae (2007)
10.1016/S0168-3659(02)00212-2
Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity.
Cristina Fonseca (2002)
10.1016/j.phrs.2010.01.009
Nanopharmacy: Inorganic nanoscale devices as vectors and active compounds.
Pilar Rivera Gil (2010)
10.1073/PNAS.95.8.4607
Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment.
S. Hobbs (1998)
10.1007/s00383-012-3162-y
Nanomedicine: a primer for surgeons
K. K. Y. Wong (2012)
10.1016/S0022-2836(64)80115-7
NEGATIVE STAINING OF PHOSPHOLIPIDS AND THEIR STRUCTURAL MODIFICATION BY SURFACE-ACTIVE AGENTS AS OBSERVED IN THE ELECTRON MICROSCOPE.
A. Bangham (1964)
10.1080/02652040802312572
Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics
Rakesh K Tekade (2009)
10.1586/ecp.11.7
Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review
A. Montero (2011)
10.1016/j.biomaterials.2009.11.077
Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers.
Caihong Zhu (2010)
10.2217/17435889.3.6.761
Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer.
M. Saad (2008)
10.3892/or.2011.1465
Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models.
T. Matsuzaki (2012)
10.1016/j.jconrel.2009.08.011
Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel.
F. Danhier (2009)
10.2147/IJN.S3061
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
E. Miele (2009)
10.1016/J.MCNA.2007.05.009
Recent advances in basic and clinical nanomedicine.
K. Morrow (2007)
10.1038/nrc1566
Cancer nanotechnology: opportunities and challenges
M. Ferrari (2005)
10.1016/j.ejps.2009.02.018
Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles.
X. R. Song (2009)
10.1208/s12249-013-9943-3
Chitosan-Modified PLGA Nanoparticles with Versatile Surface for Improved Drug Delivery
Y. Wang (2013)
10.1016/j.biomaterials.2009.02.040
Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers.
T. Lammers (2009)
Nanoliposome Potentials in Nanotherapy: A Concise Overview
K. Khosravi-Darani (2010)
10.1038/nrd1632
Recent advances with liposomes as pharmaceutical carriers
V. Torchilin (2005)
10.1016/S0958-1669(02)00282-3
Luminescent quantum dots for multiplexed biological detection and imaging.
W. Chan (2002)
10.1021/BC049951I
Toxicity of gold nanoparticles functionalized with cationic and anionic side chains.
Catherine M Goodman (2004)
10.1002/smll.200900621
Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells.
A. M. Chen (2009)
10.1111/j.2042-7158.1983.tb04831.x
Reconstituted collagen nanoparticles, a novel drug carrier delivery system.
M. El-Samaligy (1983)
10.1038/mt.2013.32
Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors.
N. Senzer (2013)
10.1177/1091581812465969
Evaluation of the Toxicity of Intravenous Delivery of Auroshell Particles (Gold–Silica Nanoshells)
S. Gad (2012)
10.1016/S0169-409X(98)00003-9
Control of tumour vascular permeability.
Baban (1998)
10.1097/CAD.0b013e328336e940
Simultaneous liposomal delivery of quercetin and vincristine for enhanced estrogen-receptor-negative breast cancer treatment
Man-Yi Wong (2010)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar